On September 18, the U.S. Food and Drug Administration (FDA) approved Opioid Analgesic Risk Evaluation and Mitigation Strategy plan, which for the first time applies to immediate-release opioid analgesics intended for use in an outpatient setting. Read more via Food & Drug Administration.